Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies

World Health Organization. Hepatitis B [ https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b ].

World Health Organization: Preventing perinatal hepatitis B virus transmission: A guide for introducing and strengthening hepatitis B birth dose vaccination. Department of Immunization, Vaccines and Biologicals 2015.

Ekra D, Herbinger K-H, Konate S, Leblond A, Fretz C, Cilote V, Douai C, Da Silva A, Gessner BD, Chauvin P. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d’Ivoire. Vaccine. 2008;26(22):2753–61.

World Health Organization. Hepatitis B vaccines. Weekly Epid Record. 2009;84(40):405–20.

Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, Schwarzer G, Greenaway C. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: A systematic review and meta-analysis. PLoS One. 2012;7(9):e44611.

Médecins Sans Frontières: Refugee health: An approach to emergency situations: Macmillan; 1997.

Vaccination in acute humanitarian emergencies: a framework for decision making [ http://www.who.int/immunization/research/meetings_workshops/5_SAGE_PDVAC_2015.pdf ].

WHO Regional Strategic Plan for Immunization 2014-2020 [ https://afro.who.int/publications/regional-strategic-plan-immunization-2014-2020-0 ].

Global policy report on the prevention and control of viral hepatitis [ http://global-report.worldhepatitisalliance.org/files/global_report/download/HEP_GlobalReport_web.pdf ].

Country operations profile - Djibouti [ http://www.unhcr.org/pages/49e483836.html ].

Mauritania: UNHCR Operational Update [ https://reliefweb.int/report/mauritania/mauritania-unhcr-operational-update-15-september-2017-enar ].

Country operations profile - Algeria [ http://www.unhcr.org/50a9f8260.pdf ].

Worldwide protracted Refugee and IDP populations [ http://www.migrationpolicycentre.eu/worldwide-protracted-refugee-idp-populations/ ].

Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31(14):1864–9.

WHO. Immunization Coverage. Immunizations, Vaccines and Biologicals, 2017. Available from: http://www.who.int/immunization/en .

Immunization Coverage [ http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html ].

Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital Casablanca. Nephrol Ther. 2005;1(5):274–84.

Maiga YI, Gassin M, Rhaly AA, Pillot J, Marjolet M, Morel D, Dicko K, Dicko I. Prevalence of hepatitis B virus in women of childbearing age in Mali. Bull Soc Pathol Exot. 1990;83(1):93–9.

Mauritania | Global Focus. [ http://reporting.unhcr.org/mauritania ].

World Population Data Sheet [ https://www.prb.org/2015-world-population-data-sheet/ ].

Tan-Torres Ejeder T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.

Lo ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39.

D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Digest Dis Sci. 1986;31(5):468–75.

Beasley RP, Lin C-C, Wang K-Y, Hsieh F-J, Hwang L-Y, Stevens C, Sun T-S, Szmuness W. Hepatitis B immune globulin (HBIg) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Lancet. 318(8243):388–93.

Fan L, Owusu-Edusei KJ, Schillie SF, Murphy TV. Cost-Effectiveness of Testing Hepatitis B–Positive Pregnant Women for Hepatitis B e Antigen or Viral Load. Obstet Gynecol. 2014;123(5):929–37.

Kim S-Y, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Org. 2007;85(11):833–42.

Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obs Gyne. 2012;207(3):231.e231–7.

World Health Organization. Life tables by country [ http://apps.who.int/gho/data/view.main.61530?lang=en ].

World Bank. Life expectancy at birth, total (years) [ http://data.worldbank.org/indicator/SP.DYN.LE00.IN ].

Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term Follow-up of Hepatitis B Vaccine in Infants of Carrier Mothers. Am J Epid. 1994;140(8):734–46.

Gavi. Hepatitis B vaccine at birth – GAVI responds to MSF [http://www.gavi.org/Library/News/Statements/2014/Hepatitis-B-vaccine-at-birth-GAVI-responds-to-MSF/].

Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP. Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980–2010). Am J Gastroenterology. 2012;107(9):1306–13.

World Health Organization. Reported estimates of HepB birth dose coverage [ http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragehepb%5Fbd.html ].

Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2005;54(16):1–32.

Stevens CE, Beasley RP, Tsui J, Lee W-C. Vertical transmission of hepatitis B antigen in Taiwan. NEJM. 1975;292(15):771–4.

Wong VCW, Reesink HW, Ip HMH, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin double-blind randomised placebo-controlled study. Lancet. 1984;323(8383):921–6.

Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard KIM, Degos F, de Moura MC, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology. 1995;21(1):77–82.

De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103(5):1630–5.

Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.

Suchy FJ, Sokol RJ, Balistreri WF. Liver disease in children: Cambridge University Press; 2014.

UNAIDS. Countries: HIV and AIDS estimates [ http://www.unaids.org/en/regionscountries/countries ].

Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis. 2011;15(2):e78–e121.

World Health Organization. Reported estimates of HepB 3-dose coverage. In: Vaccines monitoring system; 2015.

Brenzel L, Young D, Walker DG. Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC). Vaccine. 2015;33(Supplement 1):A13–20.

World Bank: GDP per capita, PPP, 1990–2015. 2017.

Hutubessy R, Chisholm D, Edejer TT-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation. 2003;1(1):8.

Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252–9.

Tilson L, Thornton L, O’Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Europ J Pub Health. 2008;18(3):275–82.

UN High Commissioner for Refugees. Resettlement: A new beginning in a third country [ http://www.unhcr.org/pages/4a16b1676.html ].

Andrus JK, Fitzsimmons J. Introduction of new and underutilized vaccines: Sustaining access, disease control, and infrastructure development. PLoS Med. 2005;2(10):e286.

World Health Organization. Global vaccine action plan [ http://www.who.int/iris/bitstream/10665/78141/1/9789241504980_eng.pdf ].

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546-1555.

Kim S-Y, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Medicine 2006;30(6):498-506.e496.

UNICEF Supplies and Logistics. Hepatitis B Vaccine Price Data. 2017. Available from: https://www.unicef.org/supply/index_57476.html .

Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, et al. A simple and inexpensive point-ofcare test for hepatitis B surface antigen detection: serological and molecular evaluation. J Viral Hepatitis 2014;21(12):905-908.